Actively Recruiting
Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-07-15
55
Participants Needed
1
Research Sites
704 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to calculate pharmacokinetic parameters and to evaluate the trough levels of posaconazole reached in patients with different stages of mucositis, due to chemotherapy and total body irradiation.
CONDITIONS
Official Title
Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients receiving allogeneic stem cell transplantation
- Treated with prophylactic posaconazole: oral suspension (200mg three times daily) or tablet (300mg once daily) to prevent invasive fungal infections
You will not qualify if you...
- Gastroparesis
- Vomiting or diarrhea within 2 hours after intake of posaconazole
- Concomitant administration of potent inducers of the enzyme UGT1A4 such as carbamazepine, phenytoin, phenobarbital, rifabutin, rifampicin
- Age under 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospitals Leuven
Leuven, Vlaams-Brabant, Belgium, 3000
Actively Recruiting
Research Team
K
Kim Vanstraelen, R.Ph.
CONTACT
I
Isabel Spriet, Pharm.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here